ATE474926T1 - Verwendung von clya hemolysin fur ausscheidung von fusionprotein - Google Patents

Verwendung von clya hemolysin fur ausscheidung von fusionprotein

Info

Publication number
ATE474926T1
ATE474926T1 AT01273749T AT01273749T ATE474926T1 AT E474926 T1 ATE474926 T1 AT E474926T1 AT 01273749 T AT01273749 T AT 01273749T AT 01273749 T AT01273749 T AT 01273749T AT E474926 T1 ATE474926 T1 AT E474926T1
Authority
AT
Austria
Prior art keywords
clya
hemolysin
excretion
fusion protein
protein
Prior art date
Application number
AT01273749T
Other languages
English (en)
Inventor
James Galen
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE474926T1 publication Critical patent/ATE474926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01273749T 2000-11-22 2001-11-23 Verwendung von clya hemolysin fur ausscheidung von fusionprotein ATE474926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25251600P 2000-11-22 2000-11-22
PCT/US2001/044185 WO2002083890A2 (en) 2000-11-22 2001-11-23 Use of clya hemolysin for excretion of fusion proteins

Publications (1)

Publication Number Publication Date
ATE474926T1 true ATE474926T1 (de) 2010-08-15

Family

ID=22956340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01273749T ATE474926T1 (de) 2000-11-22 2001-11-23 Verwendung von clya hemolysin fur ausscheidung von fusionprotein

Country Status (16)

Country Link
US (2) US7056700B2 (de)
EP (1) EP1412502B1 (de)
JP (1) JP3976685B2 (de)
AT (1) ATE474926T1 (de)
AU (1) AU2001297770B2 (de)
CA (1) CA2430322A1 (de)
CZ (1) CZ20031378A3 (de)
DE (1) DE60142646D1 (de)
ES (1) ES2349114T3 (de)
HU (1) HUP0303843A3 (de)
MX (1) MXPA03004562A (de)
NO (1) NO20032286L (de)
NZ (1) NZ525735A (de)
PL (1) PL366122A1 (de)
WO (1) WO2002083890A2 (de)
ZA (1) ZA200303851B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10208653A1 (de) * 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN105950608B (zh) * 2007-05-22 2019-12-17 康乃尔研究基金会有限公司 蛋白质在细菌及其衍生小泡表面展示的组合物和方法及其用途
WO2008147816A2 (en) * 2007-05-22 2008-12-04 Cornell Research Foundation, Inc. Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
EP2294090B1 (de) 2008-06-03 2014-05-14 University of Maryland, Baltimore NICHT HÄMOLYTISCHES ClyA FÜR PROTEINAUSSCHEIDUNG
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP3693010A1 (de) 2012-04-06 2020-08-12 Cornell University Untereinheiten-impfstoffabgabeplattform für robuste humorale und zelluläre immunantworten
BR112016022447A2 (pt) * 2014-03-28 2017-10-10 Novozymes As ressolubilização de cristais de proteína a ph baixo
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
CN110747155A (zh) * 2019-11-12 2020-02-04 湖南大学 减毒重组工程菌及其制备方法、应用和肿瘤靶向药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4355117A (en) 1980-10-08 1982-10-19 Nabisco Brands, Inc. Process for preparing agglomerated fibrous cellulose
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4665027A (en) 1983-11-03 1987-05-12 Bio-Process Innovation, Inc. Immobilized cell reactor-separator with simultaneous product separation and methods for design and use thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
KR890005273A (ko) 1987-09-09 1989-05-13 이정오 2중 실관 반응기에 의한 구연산의 연속 생산방법
DE4239612A1 (de) 1992-11-25 1994-05-26 Cultor Oy Bioreaktor mit immobilisierten, Milchsäure-produzierenden Bakterien und dessen Verwendung in Fermentationsverfahren
US5525504A (en) 1993-04-30 1996-06-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Cytolysin gene and gene product
US5731151A (en) 1993-05-24 1998-03-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Regulator of contact-mediated hemolysin
US5512480A (en) 1994-03-11 1996-04-30 Baxter International Inc. Flow-through bioreactor with grooves for cell retention
US5585266A (en) 1995-10-05 1996-12-17 Plitt; Cheryl A. Immobilized cell bioreactor
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
NO20032286L (no) 2003-07-07
JP3976685B2 (ja) 2007-09-19
HUP0303843A3 (en) 2010-01-28
EP1412502B1 (de) 2010-07-21
EP1412502A2 (de) 2004-04-28
WO2002083890A2 (en) 2002-10-24
AU2001297770B2 (en) 2007-04-05
JP2004532634A (ja) 2004-10-28
DE60142646D1 (en) 2010-09-02
PL366122A1 (en) 2005-01-24
CZ20031378A3 (cs) 2003-09-17
NO20032286D0 (no) 2003-05-21
US20020146430A1 (en) 2002-10-10
US20060147461A1 (en) 2006-07-06
CA2430322A1 (en) 2002-10-24
MXPA03004562A (es) 2003-09-10
US7459161B2 (en) 2008-12-02
NZ525735A (en) 2005-07-29
ZA200303851B (en) 2004-05-11
US7056700B2 (en) 2006-06-06
ES2349114T3 (es) 2010-12-28
HUP0303843A2 (hu) 2004-03-01
WO2002083890A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DE60144145D1 (de) Subtilisin-variante
WO2002031134A3 (en) Novel serine protease genes related to dppiv
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
IS5905A (is) Alzheimer sekretasi
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
CY1109207T1 (el) Διαδικασια εχινοκανδινης
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
ATE384787T1 (de) Tripeptidyl-aminopeptidase
DE50112186D1 (de) Expression von Alkalischer Phosphatase in Hefe
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
DK1157100T3 (da) Oxaloacetathydrolase-defekte svampeværtsceller
ATE321853T1 (de) Humanische pellino-polypeptide
DK1082423T3 (da) Cyclin E2-gener og -proteiner
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
SE9602822D0 (sv) New receptor
DE60333001D1 (de) Vac-bac-shuttlevektor-system
DK1226236T3 (da) Polypeptider, der har glucanotransferase-aktivitet, og nucleinsyrer, som koder disse
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DK1078072T3 (da) Nye peptidfragmenter til oprensning af proteiner
SE9604439D0 (sv) New receptor
BR0114719A (pt) Moléculas de aggrecanase
DE59905355D1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties